Results 81 to 90 of about 74,496 (193)
Funktionelle Charakterisierung von Mitgliedern des MicroRNA-17-92-Clusters im Blutgefäßsystem [PDF]
, 2011 Almost two decades ago, microRNAs were discovered as novel posttranscriptional regulators of gene expression. Since then, research efforts have uncovered their involvement in the control of various cellular processes including migration, proliferation ...
Döbele, Carmen
core
Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5‑d]pyrrolo[2,3‑b]pyridine Inhibitors [PDF]
, 2016 Early hit to lead work on a pyrrolopyridine chemotype provided access to compounds with biochemical and cellular potency against Janus kinase 2 (JAK2).
James Grebinski (1551433) +19 more
core +1 more source
Iraqi Journal of Hematology, 2016 Background: Myelofibrosis (MF) is largely documented by an abnormal cytokine expression, which in turn could contribute to bone marrow fibrosis, angiogenesis, and constitutional symptoms.
Shahla′a Fadhil Sabir
doaj +1 more source
Generalized granuloma annulare associated with essential thrombocythemia
Clinical Case Reports, 2020 The only myeloproliferative neoplasm associated with generalized granuloma annulare (GA) is chronic myelogenous leukemia (CML). We present the first reported case of GA in a patient with essential thrombocythemia (ET).
Sai P. Polineni, Steven Lawyer
doaj +1 more source
Leptin inhibits apoptosis in thymus through a Janus kinase-2-independent, insulin receptor substrate-1/phosphatidylinositol-3 kinase-dependent pathway [PDF]
, 2015 The cytokine-like hormone leptin is known to exert important functions on the modulation of immune responses. Some of these effects are dependent on the property of leptin to modulate the apoptosis of thymic cells.
Amaral, MEC +8 more
core +1 more source
Jak-2 mutation frequency in patients with thrombocytosis
Caspian Journal of Internal Medicine, 2018 Background: We aimed to investigate the etiologic causes and the existence of Janus kinase 2 mutation (JAK2) in cases with thrombocytosis. Methods: In this retrospective study, patients, who were admitted to hematology clinic with thrombocytosis ...
Osman Yokus, Habip Gedik
doaj
Chinese Medical Journal, 2016 Background: Recently, calreticulin (CALR) gene mutations have been identified in patients with essential thrombocythemia (ET). A high-frequency of ET cases without Janus kinase 2 (JAK2) mutations contain CALR mutations and exhibit clinical ...
Chao Sun +5 more
doaj +1 more source
Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers. [PDF]
, 2013 The discovery of the highly prevalent activating JAK (Janus kinase) 2 V617F mutation in myeloproliferative neoplasms, and of other pseudokinase domain-activating mutations in JAK2, JAK1 and JAK3 in blood cancers, prompted great interest in understanding ...
Leroy, Emilie +4 more
core +1 more source
Profile of pacritinib and its potential in the treatment of hematologic disorders
Journal of Blood Medicine, 2014 Eleftheria Hatzimichael, Evangelos Tsolas, Evangelos Briasoulis Department of Haematology, University Hospital of Ioannina, Ioannina, Greece Abstract: Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and ...
Hatzimichael E, Tsolas E, Briasoulis E
doaj